Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A narrative review synthesizing pathogenic mechanisms and clinical relationships of MASLD with metabolic syndrome, offering conceptual framework rather than new empirical evidence.
World Journal of Pharmacy and Pharmaceutical Sciences
Small single-centre animal study with surrogate biochemical endpoints and no clinical outcome; results are promising but require human validation before clinical application.
World Journal of Pharmacy and Pharmaceutical Sciences
Small animal study (n=20 rats) with surrogate biochemical endpoints and no human translation; demonstrates proof-of-concept but lacks the design and population scope needed to guide clinical practice.
A sound single-centre animal study with multiple relevant endpoints showing metabolic benefit, but limited to mice and surrogate markers; results require confirmation in humans.
This is a mechanistic study using in vitro biochemistry and cell/animal models to propose a novel pathway; it raises a question about fructose's direct effects on mitochondria rather than providing clinical evidence ready to guide practice.
This is a narrative review synthesizing preclinical mechanisms and heterogeneous clinical evidence without new primary data, raising mechanistic questions about ketogenic metabolic therapy in cancer rather than answering them with controlled evidence.
A narrative review article outlining expert recommendations for comprehensive prediabetes prevention strategies, without presenting original trial data or quantified outcomes.
A narrative review article presenting current clinical approaches to early diagnosis and prevention of metabolic disorders in type 2 diabetes risk, without original research data or systematic evidence synthesis.